Form 4: UTMD Officer Koopman Granted Stock Options

Utah Medical Products' Principal Financial Officer, Brian Koopman, was granted 500 employee stock options with an exercise price of $58.1, vesting through 2030.

Summary

• Brian Koopman, Principal Financial Officer of Utah Medical Products Inc. (UTMD), was granted 500 employee stock options.
• The transaction date for this grant was October 31, 2025.
• The exercise price for these options is $58.1 per share.
• The options will vest 25% on January 1, 2027, and an additional 6.25% on April 1, 2027, and the first day of each calendar quarter thereafter.
• The options will be fully exercisable on January 1, 2030.
• The expiration date for these options is October 31, 2035.
• Following this reported transaction, Mr. Koopman beneficially owns 5,600 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a standard compensation practice that generally aligns management interests with shareholders, which is mildly positive. It does not, however, indicate any significant operational or financial news.

Positives

• The grant of employee stock options aligns the Principal Financial Officer's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages retention of key management personnel over several years.

Future Outlook

The vesting schedule for the granted options extends through January 1, 2030, indicating a long-term incentive structure for the Principal Financial Officer, aligning future performance with equity ownership.

Industry Context

The grant of employee stock options is a common practice in the medical device industry and broader corporate landscape to compensate and incentivize key executives, linking their financial success to the company's stock performance.

Comparison to Industry Standards

• A Form 4 filing primarily reports an insider transaction and does not provide sufficient detail to conduct a specific comparison of this option grant's size, exercise price, or vesting schedule against industry benchmarks or comparable companies' executive compensation packages.

Stakeholder Impact

• Shareholders: The grant of options aims to align the Principal Financial Officer's long-term interests with shareholder value creation.
• Employees: This represents a component of executive compensation, which can influence overall compensation philosophy within the company.

Next Steps

• The options will begin vesting on January 1, 2027, and continue quarterly until fully exercisable on January 1, 2030.

Key Dates

Keywords

UTMD, Utah Medical Products, stock options, Form 4, insider transaction, executive compensation, equity grant